Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies. (3rd August 2018)

• Record Type: Journal Article
• Authors: Gujar, Shashi; Pol, Jonathan G.; Kroemer, Guido
• Is Part Of: Oncoimmunology. Volume 7:Number 8(2018)
• Publication Date: 2018-08-03
• Subjects: antibodies -- antitumor response -- antiviral response -- CTLA-4 -- immunosurveillance -- immunotherapy -- immune checkpoint -- Immunosurveillance -- Inflammation and cancer -- models of immunostimulation -- oncolytic virus -- PD-1 -- PD-L1 -- therapeutic antibodies; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1442169
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Immune checkpoint blockade is less efficient in patients bearing immunologically 'cold' tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in Science Translational Medicine show that adjuvant-like activities of oncolytic viruses make brain and breast tumors 'hot' and sensitize them for subsequent immune checkpoint blockade.